Pharmaceutical firm Icon reports good year with profits rising 92% to €45m

Irish pharmaceutical services company Icon has reported a 92% increase in annual net profits, for 2012, to $60.4 million (€45.2m.

The Dublin-headquartered firm — which, late last year, delisted from the Iseq, in favour of a full listing on New York’s Nasdaq exchange — also said earnings per share, for the year, increased from 52c to $1.

Chief executive Ciaran Murray said 2012 validated the company’s investment strategy, “as we won a record $1.6bn of new business and reported milestone revenue of $1.12bn and earnings per share of $1”.